Introduction
One of the most pressing needs in the health field is to treat the right patients with the right medicine. However, in light of the current complete lack of structure modifying treatments for osteoarthritis (OA), the even more pressing issue is to identify the optimal patient population in which to test a given treatment. For patients with OA, non-surgical treatment consists notably of physical therapy, lifestyle modification, supportive devices, medicinal pain relief, oral and injection drugs (e.g., non-steroidal antiinflammatory drugs). Once these treatments fail, surgery, such as joint replacement, is the main option for the patients. Presently, structure modification trials are in part hindered by a combination of slow and unpredictable disease progression, quantified by relatively insensitive detection tools such as X-ray criteria. To enable an optimal development program and later ensure that the right patients are treated with the optimal intervention there is a need of a method to segregate patients with different OA subtypes in order to pair them with an optimal mode of action. This may help redeem the OA clinical trial area, and lessen the chances of false negative conclusions.
Which diseases are optimal candidates for personalized health care (PHC) and what drives the need?
PHC has often been suggested as a solution 1 to this complexity, but the majority of examples of successful PHC are currently drawn from oncology and, as such, reflect a relatively simplistic concept of therapeutic stratification based on the targeting of constitutively activated pathways in an oligogenic model of disease. In contrast, reportable successes for PHC in the field of polygenic disease are few. This poses the question of whether therapeutic areas and specific diseases outside the field of oncology can ultimately benefit from a tailored approach to therapy. It seems likely that certain therapeutic areas may ultimately prove more amenable to the application of PHC than others; these would be characterized by highly heterogeneous patient populations, low response rates and significant disadvantages stemming from stochastic 'trial and error' prescribing that increases risk of adverse events and economic burden due to exploratory prescriptions of high cost therapies. Contrasting examples of the utility of a PHC paradigm are provided by osteoporosis and non-small-cell lung carcinoma (NSCLC). In osteoporosis, the need for stratification of patients is limited due to the relatively benign side effect profile and high response rates of established therapies 2e4 , and the limited complexity of the disease involving mainly one tissue, bone. Despite early reports linking the commonly prescribed bisphosphonate therapies with stratified responses in terms of bone mineralization 5 , novel clinical diagnostics have neither been extensively sought nor established, and therapeutic practice remains solely based on prognostic investigation. In contrast, following the initial characterization of a number of mutations that drive and maintain tumorgenesis 6 , diagnostic practice for NSCLC has rapidly extended beyond classical pathology; physicians now have an opportunity to target highly effective therapies against signaling pathways activated by these mutations.
For the current discussion, we identified four major drivers of PHC.
Identification of patients that are in greatest need of treatment. Identification of the patients whom may respond optimally, with the highest efficacy and lowest safety concerns, to a given treatment Development strategy for a selected subpopulation of patients. Efficient use of health care resources.
Although PHC might seem to be a highly attractive 'magic bullet' for patients, physicians, and payers, the interaction of several key considerations dictates the ultimate level of attractiveness of a PHC strategy. On the one hand, it is readily appreciated that the nontargeted treatment of a particular group of patients may not provide a cost-benefit-risk assessment that is adequately attractive [ Fig. 1(A) ]. In addition, it is equally readily apparent that restricting treatment to a diagnostically selected subpopulation with a high likelihood of a response may significantly and drastically improve this assessment [ Fig. 1(B) ], whereas another selected treatment more appropriate targets other patients [ Fig. 1(C) ], in contract to the worst-case scenario in which only non-responders and Serious adverse events (SAEs) are the result of treatment.
Given the central precept that treatment of non-responders with a therapy associated with considerable side effects and costs will only provide risk without benefit to patients and waste scarce health care resources, it would seem intuitive that treatments delivering low response rates and a high potential for side effects would have the most to gain from PHC. Identification of nonresponders will be of particular concern if the adverse effects are considered irreversible. Ethical and economic considerations clearly drive the earlier identification of such non-responders in order to allow for selection of an alternative intervention.
The heterogeneity of the patient population e lessons learned from rheumatoid arthritis (RA)
Experience with PHC in the context of RA provides an instructive example of the potential possibilities for OA. RA is a chronic autoimmune disease characterized by poly-articular inflammation resulting in massive tissue destruction in the affected synovial joints. Due to fast progression of joint structural damage that may lead to complete disability in less than 10 years, some patients need to be treated aggressively 7 , and precise guidelines from European league against rheumatology (EULAR) are provided for patient care for both synthetic and biological interventions . Methotrexate therapy (MTX), often in combination with corticosteroids, is the most commonly used Disease Modifying Anti-Rheumatic Drug (DMARD) regimen in RA 12, 13 . Upon inadequate response or intolerance to therapy, initiation of a biologic therapy is recommended 14 . There are a growing number of approved biologic therapies for RA. Given such a battery of diverse therapeutic options available to rheumatologists, it is not surprising that clinical remission of RA, or at least low disease activity, is often the goal of therapy 15, 16 . However, the absolute performance of biological therapies in randomized controlled studies in patients who have failed initial DMARD therapy is very similar based on the standardized criteria established by the American College of Rheumatology (ACR) for 20% (ACR20), 50% (ACR50) and 70% (ACR75) improvement in disease activity: namely 50e65% for ACR20, 20e 45% for ACR50 and 10e25% for ACR70 17e19 . These data reveal a heterogeneity of drug responses and point to a significant and remaining unmet need for alternative therapies for the substantial number of patients who fall short of attaining remission or low disease activity from current therapy 15 . Given the exposure of these inadequately treated patients to the risk of adverse events, together with a considerable societal economic burden of unremitting disease and cost of therapy, a PHC approach to the treatment of RA is pursued aggressively. The success will require that the current seemingly random stochastic approach to RA therapy needs to be replaced by a mechanistic and predictive understanding of response.
The heterogeneity of the patient population is heavily debated in the OA; failures in clinical trials, have made it increasingly more evident that OA is not one disease but has different phenotypes 20 .
Although the OA field is still without efficacious treatments to validate this hypothesis, several subtypes have been identified that may warrant different treatment strategies. Those subtypes receiving the most attention currently include the following: metabolic OA (including obesity) 21, 22 , traumatic OA (including joint malalignment) 23 , inflammation driven OA 24 and subchondral bone turnover driven OA phenotypes 25 . This may be illustrated schematically as shown in Fig. 2 . If a particular therapy works in a subset of patients with a specific disease phenotype, the response rates will be low in the absence of patient selection. Consequently, targeting a particular disease phenotype with the etiologically appropriate therapy would be expected to result in far higher response rates.
PHC in RA: current understanding of possible technological advances
Presently there are few positive examples of PHC for RA. Seropositivity, the presence of autoantibodies to rheumatoid factor (RF) or anticyclic citrullinated peptide (anti-CCP) observed in around 80% of patients, is an example of one type of biomarker with a modest ability to predict response to Rituximab 26 . Another approach to the identification of subgroups of therapeutic responders has been genetics based. RA has a strong, but complex genetic etiology illustrated by the identification of 31 risk loci in seropositive RA, a very strong genetic risk factor HLA-DRB1, and the group of alleles referred to as the shared epitope (SE). To date, candidate and genome wide approaches to the discovery of response genes have been taken for anti-Tumor necrosis factor (TNF) 17 and tocilizumab interventions. While associations have been established, the predictive capability has so far been insufficient to have meaningful clinical application. Wang et al. reported that polymorphisms identified in a genome wide association scan (GWAS) each accounted for less than 2% of the variance observed with change in DAS28 response to tocilizumab. Thirdly, the production of antibodies against biologic therapies, such as to anti-TNF antagonists, has also been associated with waning of drug response. Lastly, a multi-marker panel approach using 12 different markers is being pursued by Crescendo 29e31
. While this may be predictive at the group levels additional tailoring of the panel of markers and algorithm may be needed to provide a meaningful result in the clinical practice at the individual patient level. Models predicting low disease activity (DAS28 < 3.2) at 52 weeks, utilizing clinical data collected at 12 weeks, have been produced for etanercept, etanercept with MTX, and certolizumab pegol 32 . These models require validation in an independent dataset and analysis against a non-anti-TNF therapy to determine if these models are predictive of response to a specific therapy 33 . Even for RA it is too optimistic to suggest that the optimal marker combination and final selection of the right patient is present, exemplified by the discussion in the RA field "Forget personalized medicine and focus on abating disease activity" 15 .
For biomarkers to be utilized in PHC they need to be readily measurable with an acceptable level of sensitivity and specificity, accessible and reportable to physicians within a clinically actionable timeframe. As suggested above, current standard practice for RA at best provides an ACR50 response rate of 20e45% in a Fig. 2 . Schematic overview to illustrate that different subtypes of patient exist that to some extent overlap, but only though targeting of the right subpopulation the most optimal cost-benefit ratio may be achieved. (A) RA (and to an even larger extent OA) may consist of many different molecular and clinical phenotypes that remain to be identified and characterized. It is considered likely that each particular phenotype will respond differently to therapies with differing modes of action. Treatment is not currently targeted by phenotype with the consequence of an unmet medical need for a greater proportion of therapeutic responses. (B) With patient selection through PHC, a given phenotype may be selected with a greater potential to respond to a specific therapy. randomized controlled trial [ Fig. 3(A) ]. By excluding patients unlikely to respond to the treatment the response rate may be increased and a subset of patients will not be exposed unnecessarily [ Fig. 3(B) ]. Thus an optimal strategy will both ensure a significant increase in response rates, but will also allow for exclusion of those patients likely to have a serious treatment related side effect.
A range of technologies may assist the implementation of PHC. While such technologies must be technically robust, relatively inexpensive, and easily accessible and simple to use, they are not limited to the current generation of non-invasive biochemical markers. A type of molecular marker has been developed that can quantify the levels of tissue destruction associated with a progressing pathology 34, 35 . In contrast to total protein measurements of established inflammatory biomarkers, such as interleukin (IL)-1, IL-6 and C-reactive protein (CRP), these new biomarkers rely on the measurement of specific, circulating tissue protein fragments generated by up-regulated, active proteolytic enzymes. As an example, the major extracellular matrix (ECM) proteins of connective tissue in joints are type I, II and III collagen. Matrix metallo protease (MMP)-mediated degradation of these collagens results in the generation of the specific biomarkers, e.g., C1M, C2M and C3M respectively 36, 38 . Additional protein fingerprints are generated by distinct enzymatic processing of collagen or other ECM proteins represented by the e.g., products like CTX-I, ICTP, CTX-II, C2C, ARGS (aggrecan), FFGV (aggrecan), C4M (type IV collagen), C5M (type V collagen) and C6M (type VI collagen) 1, 39 . The measurement of different degradation products of a protein may elucidate different and frequently opposing metabolic mechanisms. This concept is exemplified by e.g., products of metabolism of type I collagen like: PINP, CTX-I, C1M and ICTP e each of these products provides distinct and unique information. PINP is a pro-peptide released during protein synthesis and can be measured as a surrogate biomarker of both bone formation and fibrogenesis 40, 41 . CTX-I is a widely used biomarker for Cathepsin K mediated destruction of type I collagen, reflecting bone resorption 42 . ICTP is a triple cross-linked carboxyterminal telopeptide of type I collagen generated by MMP-activity, but destroyed by the activity of other proteases 43 . ICTP is mainly released from connective tissue turnover. Finally, C1M is also released by the action of MMP's from the helical domain of type I
collagen. These different products of type I collagen provide different and complementary information on tissue integrity and turnover even though they in essence are measures of the same protein, albeit in different ways.
What does this mean for the OA field?
The list of failures and limited successes in clinical development for OA is growing, and includes among others, Inducible nitric oxide synthase (iNOS), strontium ranelate, Calcitonin, MMP inhibitors, Cathepsin K inhibitors and bisphosphonates 44e47 . These disappointing results may in part be due to hypothesis failures but also a result of applying these therapies to non-selected patient populations. Figure 4 offers a very preliminary but possibly clinically meaningful and clinically feasible strategy for selecting OA patients. OA might be divided into at least three different subtypes based on the most active joint tissue at a particular stage of disease (bone, cartilage and inflamed synovium) or the tissue with the predominant manifestations in particular patient populations. As examples, Treatment 1 may target early cartilage pathology such as manifested in traumatic OA, with high protease activities in the articular cartilage such as MMP and aggrecanase activities. Treatment 2 would target both bone and cartilage involvement, such as manifested in postmenopausal generalized OA. Treatment 3 may target late stage inflammation driven OA. Clearly these three different subtypes of OA would require different interventions and diagnostic algorithms, and one treatment that may be successful in one patient population may fail in another.
Based on even this simplistic subdivision of patients groups, the following treatment scenarios might be suggested.
Patient phenotype 1: Traumatic OA, in the early disease course most likely involving a high level of protease activity destroying the cartilage subsequent to cartilage injury. These patients might benefit from a protease inhibitor treatment. Patient phenotype 2: Generalized OA, with high turnover of bone and progression of cartilage damage characterized by an intimate relationship between bone and cartilage in the pathogenesis of OA. These patients may benefit from an anti- Fig. 3 . (A) Treatment of the entire patient population, without preselection of patients, resulting in 30% response rates. (B) Preselecting 50% of patients may result in a 60% response rate, thus drastically improving the cost-benefit and benefit-risk assessments. Importantly, PHC is of benefit for not only identifying those patients who will respond safely to treatment, but also those patients who should not be exposed to the drug. Thus, an optimal strategy will both ensure an enrichment of response rates, and lower adverse event rates through exclusion of patients from the treatment pool for whom the therapy poses a serious risk. Importantly, SAEs can and may also occur in selected patients, as illustrated by the "half-man" being a non-responder as well as subject to an SAE. resorptive treatment inhibiting bone resorption and subchondral bone turnover. Patient phenotype 3: Episodic subacute and acute inflammatory events precipitating worsening in stages. Macrophages play a role in this process 48 and likely will yield pathways to inform specific anti-inflammatory therapies for this phenotype or stage of disease.
This approach underscores the need to better understand the multiple pathways that result in the common end stage we refer to as OA. While these delineations may overlap to some extent and be dependent on the time and stage of disease, the scenarios represent testable hypotheses that call for further research to validate and refine algorithms for clinically meaningful patient phenotyping.
Do different phenotypes in OA represent different pathological stages and/or different phenotypes?
It is important to recognize that OA is far from a static disease, and represents very distinct characteristics during the various stages of disease progression, i.e., the above mentioned phenotypes may vary over time. The different phenotypes of OA 21 most likely depend on many factors such as metabolic, traumatic, genetic and lifestyle dependent factors. Currently we may understand that OA may be triggered by a macro-or micro-traumatic injury to the joint, where the trauma can be an acute accident or daily microinjury respectively. Such events result in high turnover of the bone and cartilage compartments, which eventually leads to symptomatic OA and joint failure, as illustrated in Fig. 5 . It will be important to improve our ability to identify factors that identify the various phenotypes of OA; to the extent to which we can more precisely identify these phenotypes, the more capable we will be at developing personalized treatments. Currently several factors related to OA disease progression may be identified including the following (as outlined in Fig. 5 ), which needs further experimental evidence and independent validation: (1) Low grade autoimmunity possibly plays a role in a subset of patients in whom there is epitope spreading from the injured joint and activation of the innate immune system 49e51 ; (2) Inflammation, in which release of factors such as cytokines and matrikines act as pro-inflammatory factors 49, 52 ; (3) ; and (6) Mechanotransduction, in which mechanical loading may drive a "wear and tear" effect. Importantly, some factors may predispose at individual stages to either slow or fast progression; these are discussed and outlined in Table I . Of key importance, the risk factors and analysis methods outlined in Table I , may optimally be used in combination rather than stand alone technologies, in which imaging [X-ray and magnetic resonance imaging (MRI)], standard demographic description, genetic and novel biomarkers together provide value to patients. Such combination of modalities, imaging, demographic and serological biomarkers has in a few clinical settings been shown to provide additional improvement in odds ratios for identification of i.e., progression 55 .
A few factors of relevance to the different type/stages of OA are given attention. The release of citrullinated fragments of different ECM proteins as well as intracellular proteins has been shown to act as autoantigens. To date, one such fragment, VICM, has been identified and shown to predict radiographic joint disease progression in a subset of patients 56 . Genetic factors may also be of particular importance as GDF5 mutations 57 have been shown to predispose to a lack of repair potential, which may be of paramount importance after traumatic injury. In addition, there are a long list of genes that are related to cartilage and bone metabolism such as Receptor activator of nuclear factor kappa-B ligand (RANK), RANK-L, Sclerostin, Cathepsin K, V-ATPase, CLC-7, MMP-9 and -2, that may influence the traumatic and high turnover stage of disease 58, 59 .
Further, our current understanding of OA suggests that inflammation may be a driver of disease albeit not an initiator of disease, as mutations in IL-1, predispose to inflammation and consequently fast progression in OA 24, 60 . This would be consistent with the biology of IL-1 and IL-1 receptor in chondrocyte function and cartilage degradation 61 . In parallel to RA where early radiographic Fig. 5 . The present figure illustrates key drivers of the disease and their speculated impact on the rate of disease progression. These distinct drivers of disease may be highly OA stage dependent and overlap to some extent. The length of the line is considered the relative importance, as such the line is longer for hormonal than autoimmunity driven OA disease, and consequently autoimmunity may lead to joint failure faster than hormonal regulations. All cases of OA may be caused by a minor or major joint trauma; however the rate of progression may be driven and accelerated by different factors. These factors may describe different OA phenotypes, and these factors may also be applied as tools for PHC allowing early segregation of patient as compared to traditional clinical diagnosis of symptomatic OA. Note that this figure provides a working hypothesis (and is hypothetical) as we do not know whether genetic factors are more important leading to faster progression (shorter length of the line) than e.g., mechano-transduction. Fig. 4 . The drivers of OA may be divided into at least three different categories: bone, cartilage and inflamed synovium. These may represent different disease subgroups; alternatively they may represent the predominant tissue pathology during a particular stage of disease. Optimal therapy may be considered the ability to detect and target each of these stages or subgroups of disease.
damage in RA is a paramount predictor of later damage 62 , a similar concept is applied to OA where different imaging modalities clearly may assist in delineating different phenotypes and progression 55, 63, 64 . These combined highlighted modalities, in addition to the traditional risk factors; age, significant trauma, obesity, altered gait, altered biomechanics (for example, a varus or valgus deformity), and excessive loading on the affected joint 65, 66 , may be part of a proposition for PHC in OA.
One relevant example of PHC in OA may be found in the recent fibroblast growth factor (FGF)-18 studies. In a retrospective analysis of data from a clinical trial with Sprifermin (rhFGF18) 67 , a combination of two SNPs in the IL1RN gene could be indicative of disease severity/progression as well as potential response to Sprifermin in defined genetic groups 68 . Four groups of patients were identified and tested for a statistical association with change in cartilage thickness/volume (as measured by MRI) and WOMAC scores. Groups of patients stratified for the SNPs rs9005 and rs315952 showed better response to Sprifermin therapy in terms of cartilage volume 68 .
This genetic stratification may be combined with serological technologies or other biomarkers such as described in Table I to further improve the prediction.
Which technological advances may facilitate the advent of PHC for the OA field?
The OA field is somewhat behind the RA field, although also in the RA field stratified phenotype directed treatment is also still in development This difference in the available toolbox, critical to the success of PHC, is most likely due to the current lack of successful intervention strategies in OA. This is further underscored by the almost accepted postulation in the OA field that novel treatments may more readily be identified and developed by identification of the right subpopulation of OA patients. Consequently, this discussion is reminiscent of the chicken and the egg discussion. However, with the emerging BIPED categorization and stratification of biochemical markers in the OA field 69 , tools are beginning to be identified that may assist in the advent of PHC for OA. Different methodologies are being classified as reflecting Burden of disease (B), Investigative (I), Prognostic (P), Efficacy of intervention (E), Diagnostic (D) and (S) Safety 69, 70 . Of most importance for PHC would be Prognostic markers at baseline that could predict optimal responders and Safety markers. Table I lists some of the genetic risk factors identified in GWAS studies, biochemical markers, and imaging markers which may facilitate the establishment of a PHC paradigm in OA by helping to define optimal patient populations for specific interventions.
We suggest that there needs to be a focused effort on PHC that could be initiated in existing cohorts. PHC efforts could be grounded in analyses of markers such as those listed in Table I , to identify patients most likely to respond to a particular treatment. In addition, in other fields, marker panels are emerging for specific organ toxicity, such as the acute kidney injury panel 71 , which is in direct alignment with the suggestion of the "FDA critical path" that the efficacy marker of one pathology may be the safety marker of another 1 . Such public efforts may assist in generating a better roadmap for drug development in the OA field, by identification of the OA patient in whom safety indicators are optimized. Such efforts should also provide quicker and safer decision making in drug development that are of paramount importance for pharmaceutical companies to commit the needed investments in later stage clinical development. These efforts are expected to further lower the investment barrier, allowing more optimal clinical trial design for critical POC studies allowing for trials with fewer patients and shorter trial durations to reach an objective decision point. The best biomarkers would improve success related to the following:
1. Identification of fast progressors 2. Identification of the optimal patients for a specific type of intervention 3. Enablement of phase II and III studies with fewer patients 4. Decreasing cost of trials 5. Minimizing drug-related adverse events 6. Potentially providing early confidence in mechanism of action 7. Surveillance for off-target effects
Conclusion
In conclusion, experience to date suggests that most medicines need to be developed to target specific subpopulations. We propose that OA is a suitable candidate for the application of PHC. As novel technologies and advanced clinical chemistry approaches, such as protein fingerprints or other robust methodologies, become a reality, the feasibility of PHC increases. The ever increasing prospect of PHC offers hope for a better future for patients, physicians and payers. Demographic Age, significant trauma, obesity, altered gait, altered biomechanics (varus or valgus deformity), and excessive loading on the affected joint 65, 66 Imaging MRI assessment of the joint including; cartilage surface, damage/lesions, synovitis, Bone morrow edema (BME), osteophytes and subchondral bone (shape and trabecular structure) in addition to other advanced technologies 55, 63, 64 Author contributions
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